Catch up with Matt Davis’ talk on “Neoantigen Targeted Cancer Immunotherapy in the Clinic” at Advance Genetic Sequencing Virtual Conference 2021

Catch up with Matt Davis’ talk on “Neoantigen Targeted Cancer Immunotherapy in the Clinic” at Advance Genetic Sequencing Virtual Conference 2021

Matt Davis PhD joined Gritstone Oncology (NASDAQ: GRTS) in 2015 and is currently the Director of Molecular Biology and Sequencing responsible for various neo-antigen discovery and translational genomics efforts.  Prior to Gritstone, Dr. Davis conducted post-doctoral research at Warp Drive Bio in the discovery biology group.  He holds a PhD in Genetics from Yale with thesis research under the supervision of Dr. Joseph Schlessinger and previous to his graduate work he conducted cancer genomics research at Dana Farber Cancer Institute and the Broad Institute. Marketsandmarkets took this opportunity to talk…

Read More

Ning Wang talks about “Single cell sequencing: a powerful approach to profile tumor microenvironment” at Advance Genetic Sequencing Virtual Conference 2021

Ning Wang talks about “Single cell sequencing: a powerful approach to profile tumor microenvironment” at Advance Genetic Sequencing Virtual Conference 2021

Ning is a bioinformatics scientist at Arcus Biosciences, where he is responsible for drug discovery, target identification, and indication prioritization in multiple immune-oncology drug programs. Notably, Ning pioneered the 3D organoids based drug response prediction technology, which largely facilitated cancer model selection. During his PhD, he studied with Professor Alexander Hoffmann at UCLA, where he built up computational framework to identify synergy between key immune response signaling pathways in macrophage. Ning holds a PhD in Bioinformatics from UCLA. Marketsandmarkets took this opportunity to pick his brains on the newfound developments…

Read More

Grace Zhao, Co-founder, Avida Biomed discusses- “Dual methylation and mutation analysis from a single input of plasma cfDNA without sample splitting”

Grace Zhao, Co-founder, Avida Biomed discusses- “Dual methylation and mutation analysis from a single input of plasma cfDNA without sample splitting”

Grace Zhao is a co-founder of Avida Biomed, a biotech start-up specializing in genomic technology innovation for molecular diagnostics. At Avida, Grace co-invented Point-n-Seq, a new platform technology to advance liquid biopsy for early detection of cancer and other diseases. Utilizing the ultra-efficient, hybridization-based pre-amplification enrichment of target molecules from nanogram level cell free DNA (cfDNA), Point-n-Seq enables the first targeted mutation and methylation cfDNA dual analysis solution on market. Grace is currently the head of clinical research defining and executing company-wide clinical research strategy. Before Avida, Grace co-founded AccuraGen,…

Read More

An Overview of Spatial Transcriptomics: Techniques and Applications With Cátia Moutinho of GWCCG

An Overview of Spatial Transcriptomics: Techniques and Applications With Cátia Moutinho of GWCCG

Dr. Cátia Moutinho is the Associate Director of Garvan-Weizmann Centre for Cellular Genomics, at the Garvan Institute Sydney-Australia. Also, she is the Group Leader of the Single Cell Technology Development Team. Her group focuses on single-cell genomics development. She is a biologist by training, with a PhD in Biomedicine and a master in Clinical Trials and Medical Affairs. She has an extensive experience in the wet-lab, with a strong background in single-cell technology, as well as cancer genetics and epigenetics. Cátia is also co-founder of the Single-Cell Ninjas Project, a…

Read More

Discovering the future of infection prevention and control – 6th Edition Infection Control, Sterilization & Decontamination Virtual Conference 2021

Discovering the future of infection prevention and control – 6th Edition Infection Control, Sterilization & Decontamination Virtual Conference 2021

July 12th, 2021- Following up the legacy of 5 very successful annuals in UK & Europe geographies, we are proud to to announce the 6th Edition Infection Control, Sterilization & Decontamination Virtual Conference, Middle East, scheduled for 5th-6th October, 2021. This edition will focus on key topics like the utilization of reprocessed equipment to disinfect or sterilize medical devices, decontamination of surgical instruments, endoscopic devices, respiratory care devices, and reusable hemodialysis machines. How Patient-to-patient pathogen transmission via medical devices can be entirely prevented by properly sterilising medical devices. These topics…

Read More

Delve into the new era of genome sequencing- MarketsandMarkets Advanced Genetic Sequencing Virtual Conference

Delve into the new era of genome sequencing- MarketsandMarkets Advanced Genetic Sequencing Virtual Conference

July 12th, 2021- Genome sequencing is providing physicians with more data about the causes of cancer and changing the way some forms of the disease are treated. Continued advancements in sequencing technologies have fuelled the development of new sequencing applications. MarketsandMarkets is proud to announce the first edition of Advanced Genetic Sequencing Virtual Conference scheduled to be held on 23rd & 24th of September 2021. A 2-day content-rich program combining stellar expertise from world-renowned keynote and featured speakers in the areas of Genetics & Genomics an expanding field of biology…

Read More

Discussing the latest IO developments at the 5th Annual MarketsandMarkets Next-Gen Immuno-Oncology Virtual Congress 2021

Discussing the latest IO developments at the 5th Annual MarketsandMarkets Next-Gen Immuno-Oncology Virtual Congress 2021

July, 08th 2021 – 5th Annual MarketsandMarkets Next-Gen Immuno-Oncology Virtual Congress 2021 to be held on the 26th-29th October 2021 will host top tier institutes pharmaceutical, bio-pharmaceutical and biotechnology companies like Scancell, Regeneron Pharmaceuticals, Cancer Vaccines Ltd, Boston Immune Technologies & Therapeutics & more to deliver the key challenges and future directions in IO research and to discuss the latest updates in development of ADC’s, Bispecific Antibodies, Cellular Therapy and Immune Checkpoint Inhibitors    The conference aims to bring together 25+ industry thought leaders & 200+ attendees from pharmaceutical and…

Read More

“Tumor-targeted costimulatory trimerbodies for cancer immunotherapy.”- A brief discussion with Juan Perez Villar, CEO, LeadArtis.

“Tumor-targeted costimulatory trimerbodies for cancer immunotherapy.”-  A brief discussion with Juan Perez Villar, CEO, LeadArtis.

Doctor in Immunology from the Autonomous University of Madrid (Spain), extensive international career in the biopharmaceutical industry at Astellas Inc. and Bristol-Myers Squibb Co. (USA). Experienced R&D leader in immune-oncology (IO). Previously, participated in preclinical development of CD28 biologic modulators for inflammatory conditions, small molecule tyrosine kinase inhibitors and fully human antibodies for advanced solid tumors at Leadartis. He advanced the company from start to capitalize on the immuno-oncology (IO) market. Evaluated and repositioned the platform technology to create IO bispecific antibody dominance and created a proprietary next generation product…

Read More

Héctor Pérez Montoyo, of Ability Pharma discusses his research on, “ABTL0812, a new immunotherapeutic anticancer agent at phase 2b clinical stage.”

Héctor Pérez Montoyo, of Ability Pharma discusses his research on, “ABTL0812, a new immunotherapeutic anticancer agent at phase 2b clinical stage.”

Héctor’s work has always focused on understanding the molecular pathophysiological mechanisms leading to autoimmunity and cancer development, investigating mechanism of action of newly developed molecules to treat such diseases. He started his career in 2006 when he moved to UT Southwestern Medical Center in Dallas (EEUU), to carry out this thesis in developing novel therapeutic antibodies in murine models of human autoimmune diseases. After obtaining his Ph.D., he combined two postdoctoral grants in Barcelona (Metastasis and Transformation group in Bellvitge Biomedical Research Center) and in Valencia (Autoimmune Pathology Lab in…

Read More

Dr. William Williams of Briacell Therapeutics Corporation talks about Personalized, off-the-shelf cellular immunotherapy for cancer

Dr. William Williams of  Briacell Therapeutics Corporation talks about Personalized, off-the-shelf cellular immunotherapy for cancer

Dr. Williams is the President and CEO of BriaCell Corporation, where he has shepherded Bria-IMT™ into the clinic, established positive proof-of-concept, forged a collaboration with Incyte for novel combinations and coordinated the development of an off-the-shelf personalized approach to cancer immunotherapy. While at Incyte Corporation as Head of Exploratory Development, he brought numerous molecules into the clinic and established proof of concept in several disease areas. At GlaxoSmithKline he worked to bring several molecules into the clinic, ran a biomarker laboratory and spearheaded initiatives to utilize emerging technologies in drug…

Read More